INOVATENCT07134153
Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
At risk: Primary completion moved 5 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 18 words Show 5 more changesShow less
- Primary endpoints: details revised at 1 of 12 entries
- Primary completion pushed from Aug 30, 2026 to Jan 30, 2027
- Study completion pushed from Feb 28, 2027 to Jun 28, 2027
- Start date: Apr 18, 2025 to May 12, 2025
- Study description expanded, about 36 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment
Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy
HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases
T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases
T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
Drugs: T-DXd
Sites
2 sites in 1 country